NovoCure Limited Earnings Recaps
Q1 2026
May 1, 2026
NovoCure shares surged 39.3% following Q1 2026 earnings, as the launch of Optune Pax for pancreatic cancer surpassed investor expectations with rapid adoption, early prescription momentum, and a major payer coverage win.
Key takeaways
- NovoCure’s U.S. launch of Optune Pax for locally advanced pancreatic cancer saw 169 prescriptions and 90 patient starts within the first seven weeks post-FDA approval; end-of-quarter backlog signals sustained demand.
- Elevance Health (covering 30 million lives) issued first major payer coverage policy for Optune Pax in the quarter, providing early validation for reimbursement.
- Active patient counts and net revenues both achieved double-digit year-over-year growth, with core GBM business growing 9% in active patients globally.
- Product enhancements, such as improved TTFields arrays and patient support tools, contributed to higher therapy persistence rates, increasing to 73% from below 70% in recent years.
- Clinical progress included PANOVA-4 trial results showing a 74% disease control rate with TTFields in metastatic pancreatic cancer and encouraging data supporting combinations with emerging targeted therapies.
Q3 2025
Oct 31, 2025
Novocure's Q3 2025 results show steady growth in glioblastoma patients, but challenges persist in launching its non-small cell lung cancer therapy, leading to flat U.S. growth.
Key takeaways
- Active glioblastoma patient count reached a record 4,277, marking a significant year-over-year increase driven by strong gains in France, Japan, and Germany.
- Novocure's non-small cell lung cancer therapy faced launch challenges, concluding the quarter with only 100 patients on treatment, with lackluster growth expectations.
- A recent positive coverage decision in Spain signals potential revenue growth, although expansion will take time due to the fragmented healthcare environment.
- Upcoming launches for pancreatic cancer and brain metastases therapies are on track, aligning with the company's strategic transition to a multi-indication therapy platform.